In today’s episode, we had the pleasure of speaking with Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO, about the potential clinical implications of the phase 3 IRAKLIA (NCT05405166) and phase 2 IZALCO (NCT05704049) studies, which investigated the use of isatuximab-irfc (Sarclisa) administered via an on-body delivery system in patients with relapsed/refractory multiple myeloma. Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Jacksonville, Florida. Faiman is a nurse practitioner in the Multiple Myeloma Program at Cleveland Clinic in Ohio.
In our exclusive interview, Ailawadhi and Faiman discussed the rationale for efforts to bring isatuximab on-body injectors into the clinic, key patient-reported outcome findings from these studies, and how these findings may one day influence therapy administration across the broader multiple myeloma treatment paradigm.
View all episodes
